NASDAQ:CLSD Clearside Biomedical Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Clearside Biomedical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.73 +0.04 (+2.37 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$1.66Now: $1.73▼$1.7550-Day Range$1.55MA: $1.70▼$1.8452-Week Range$0.60Now: $1.73▼$4.13Volume109,691 shsAverage Volume612,862 shsMarket Capitalization$80.17 millionP/E RatioN/ADividend YieldN/ABeta0.94 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingClearside Biomedical has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.75, Clearside Biomedical has a forecasted upside of 232.4% from its current price of $1.73.Amount of Analyst CoverageClearside Biomedical has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesClearside Biomedical has received 305 “outperform” votes. (Add your “outperform” vote.)Underperform VotesClearside Biomedical has received 258 “underperform” votes. (Add your “underperform” vote.)Community SentimentClearside Biomedical has received 54.17% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote “Outperform” if you believe CLSD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldClearside Biomedical does not currently pay a dividend.Dividend GrowthClearside Biomedical does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clearside Biomedical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $498,943.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 13.10% of the stock of Clearside Biomedical is held by insiders.Percentage Held by InstitutionsOnly 25.45% of the stock of Clearside Biomedical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clearside Biomedical are expected to grow in the coming year, from ($0.47) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearside Biomedical is -3.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearside Biomedical is -3.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearside Biomedical has a P/B Ratio of 6.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.93 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLSD Previous Symbol CUSIPN/A CIK1539029 Webwww.clearsidebio.com Phone678-270-3631Debt Debt-to-Equity Ratio0.17 Current Ratio1.77 Quick Ratio1.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.17 million Price / Sales36.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book6.92Profitability EPS (Most Recent Fiscal Year)($0.81) Net Income$-30,770,000.00 Net Margins-280.03% Return on Equity-189.40% Return on Assets-76.70%Miscellaneous Employees50 Outstanding Shares46,342,000Market Cap$80.17 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $1.73 +0.04 (+2.37 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CLSD News and Ratings via Email Sign-up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions How has Clearside Biomedical's stock been impacted by Coronavirus? Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLSD stock has decreased by 33.2% and is now trading at $1.73. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Clearside Biomedical? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Clearside Biomedical. When is Clearside Biomedical's next earnings date? Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Clearside Biomedical. How were Clearside Biomedical's earnings last quarter? Clearside Biomedical Inc (NASDAQ:CLSD) issued its quarterly earnings results on Monday, August, 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.13). The firm had revenue of $0.35 million for the quarter, compared to analysts' expectations of $1.44 million. Clearside Biomedical had a negative net margin of 280.03% and a negative return on equity of 189.40%. View Clearside Biomedical's earnings history. What price target have analysts set for CLSD? 5 equities research analysts have issued 1-year price objectives for Clearside Biomedical's stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Clearside Biomedical's stock price to reach $5.75 in the next year. This suggests a possible upside of 232.4% from the stock's current price. View analysts' price targets for Clearside Biomedical. Who are some of Clearside Biomedical's key competitors? Some companies that are related to Clearside Biomedical include Concert Pharmaceuticals (CNCE), Urovant Sciences (UROV), Chiasma (CHMA), Menlo Therapeutics (MNLO), VYNE Therapeutics (VYNE), Aquestive Therapeutics (AQST), Paratek Pharmaceuticals (PRTK), Xeris Pharmaceuticals (XERS), Affimed (AFMD), Aldeyra Therapeutics (ALDX), Cyclerion Therapeutics (CYCN), Liminal BioSciences (LMNL), Osmotica Pharmaceuticals (OSMT), Neptune Wellness Solutions (NEPT) and Selecta Biosciences (SELB). View all competitors. What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), OrganiGram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE) and Cannabics Pharmaceuticals (CNBX). Who are Clearside Biomedical's key executives? Clearside Biomedical's management team includes the following people: Dr. George M. Lasezkay Pharma.D., J.D., Interim CEO & Director (Age 67)Mr. Charles A. Deignan, Chief Financial Officer (Age 55)Mr. Stephen C. Kilmer, Investor Relations Officer (Age 53)Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 50)Mr. Rick McElheny, VP of Corp. Devel. When did Clearside Biomedical IPO? (CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. What is Clearside Biomedical's stock symbol? Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD." Who are Clearside Biomedical's major shareholders? Clearside Biomedical's stock is owned by a variety of retail and institutional investors. Top institutional investors include RTW Investments LP (8.45%), Bridgeway Capital Management Inc. (0.40%), Jane Street Group LLC (0.12%), Principal Financial Group Inc. (0.08%), Principal Financial Group Inc. (0.08%) and Charles Schwab Investment Management Inc. (0.06%). Company insiders that own Clearside Biomedical stock include Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson and William D Humphries. View institutional ownership trends for Clearside Biomedical. Which institutional investors are buying Clearside Biomedical stock? CLSD stock was acquired by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Principal Financial Group Inc., Principal Financial Group Inc., RTW Investments LP, Charles Schwab Investment Management Inc., Johnson Investment Counsel Inc., First Citizens Bank & Trust Co., and Jane Street Group LLC. Company insiders that have bought Clearside Biomedical stock in the last two years include Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson, and William D Humphries. View insider buying and selling activity for Clearside Biomedical. How do I buy shares of Clearside Biomedical? Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Clearside Biomedical's stock price today? One share of CLSD stock can currently be purchased for approximately $1.73. How big of a company is Clearside Biomedical? Clearside Biomedical has a market capitalization of $80.17 million and generates $2.17 million in revenue each year. The company earns $-30,770,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe. What is Clearside Biomedical's official website? The official website for Clearside Biomedical is www.clearsidebio.com. How can I contact Clearside Biomedical? Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
